Cassava Sciences, Inc.

Equities

SAVA

US14817C1071

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
20.23 ^USD	-4.17%		-8.25%	-10.13%

May. 10	Cassava Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 08	Cassava Sciences Raises More Than $125 Million From Warrant Distribution	MT

Pain Therapeutics, Inc. Announces Resignation of Peter S. Roddy as Vice President, Chief Financial Officer and Secretary

February 17, 2017 at 09:01 am EST

On February 14, 2017, Peter S. Roddy resigned, effective March 9, 2017, as Vice President, Chief Financial Officer and Secretary of Pain Therapeutics, Inc. to pursue a job opportunity in the San Francisco Bay Area.

Latest news about Cassava Sciences, Inc.

Cassava Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 10	CI
Cassava Sciences Raises More Than $125 Million From Warrant Distribution	May. 08	MT
North American Morning Briefing : Stock Futures -2-	May. 06	DJ
North American Morning Briefing : Investors Brace -2-	Apr. 29	DJ
Cassava Sciences Announces Completion of Interim Safety Review for Alzheimer's Drug Candidate Simufilam	Mar. 25	MT
Cassava Sciences, Inc. Announces Completion of an Interim Safety Review of Oral Simufilam On-Going Phase 3 Trials	Mar. 25	CI
Cassava Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Cassava Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Cassava Sciences, Inc. Reports Results of Two-Year Clinical Safety Study of Simufilam, an Investigational Oral Drug for the Proposed Treatment of Alzheimer?s Disease Dementia	Feb. 07	CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 2000 Index	Jan. 08	CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 3000 Index	Jan. 08	CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 2500 Index	Jan. 08	CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell Small Cap Completeness Index	Jan. 08	CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell Small Cap Comp Growth Index	Jan. 08	CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 3000 Growth Index	Jan. 08	CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 2500 Growth Index	Jan. 08	CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 3000E Index	Jan. 08	CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 3000E Growth Index	Jan. 08	CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 2000 Dynamic Index	Jan. 08	CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 2500 Dynamic Index	Jan. 08	CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 2000 Growth-Dynamic Index	Jan. 08	CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 2500 Growth-Dynamic Index	Jan. 08	CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 2000 Growth Index	Jan. 08	CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from S&P TMI Index	Jan. 08	CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from S&P Pharmaceuticals Select Industry Index	Jan. 08	CI

Chart Cassava Sciences, Inc.

Duration

Period

More charts

Company Profile

Cassava Sciences, Inc. is a biotechnology company focused on Alzheimer's disease. The Company's science is based on stabilizing, but not removing, a critical protein in the brain. The Company is focused on its product discovery and development efforts on disorders of the nervous system. Its lead therapeutic drug candidate, simufilam, is under clinical evaluation for the proposed treatment of Alzheimer's disease dementia in Phase 3 clinical studies. The Company has two biopharmaceutical assets under development. Its lead therapeutic product candidate, called simufilam, is an oral treatment for Alzheimer's disease dementia. Its lead investigational diagnostic product candidate, called SavaDx, is a way to detect the presence of Alzheimer's disease from a small sample of blood. Simufilam targets an altered form of a protein called filamin A in the Alzheimer's brain. It owns rights to its drug and diagnostic assets and related technologies, without royalty obligations to any third party.

Sector

Biotechnology & Medical Research

Calendar

2024-07-30 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

20.23 USD

Average target price

99.5 USD

Spread / Average Target

+391.84%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CASSAVA SCIENCES, INC.	-10.13%	875M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs